This novel DNMTI-specific DNA hypomethylation pattern triggers dual inhibition of PI3K-AKT and CDK2-Rb and inactivation of GSK3β, leading to enhanced tumor regression in comparison to that of a PI3K inhibitor. The gene discussed is CDK2; the disease is neoplasm.